Aclarion Inc
ACONW0.037USD
-0.001-1.32%
Close （ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Aclarion Inc Company
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS), and proprietary biomarkers to optimize clinical treatments. It has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that the Company has demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. It uses a magnet to apply a pulsed magnetic field to a patient, sensors to detect radio waves that emanate from the resonant vibrations of different chemicals in the body in response to that pulsed magnetic field and a computer to create detailed images of tissue structures in the patient based on those detected chemical signals.
Aclarion Inc Info
Ticker SymbolACONW
Company nameAclarion Inc
IPO dateApr 22, 2022
CEOMr. Brent Ness
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address8181 Arista Place
CityBROOMFIELD
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code80021
Phone18332752266
Websitehttps://aclarion.com/
Ticker SymbolACONW
IPO dateApr 22, 2022
CEOMr. Brent Ness
Company Executives of Aclarion Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Gregory A. (Greg) Gould
Mr. Gregory A. (Greg) Gould
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Brent Ness
Mr. Brent Ness
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Steve Deitsch
Mr. Steve Deitsch
Independent Director
Independent Director
--
--
Mr. William Wesemann
Mr. William Wesemann
Lead Independent Director
Lead Independent Director
--
--
Mr. Ryan Bond
Mr. Ryan Bond
Chief Strategy Officer
Chief Strategy Officer
--
--
Ms. Amanda Williams
Ms. Amanda Williams
Independent Director
Independent Director
--
--
Mr. David Neal
Mr. David Neal
Director
Director
--
--
Dr. Scott Breidbart, M.D.
Dr. Scott Breidbart, M.D.
Independent Director
Independent Director
--
--
Dr. Jeff Thramann, M.D.
Dr. Jeff Thramann, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Gregory A. (Greg) Gould
Mr. Gregory A. (Greg) Gould
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Brent Ness
Mr. Brent Ness
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Steve Deitsch
Mr. Steve Deitsch
Independent Director
Independent Director
--
--
Mr. William Wesemann
Mr. William Wesemann
Lead Independent Director
Lead Independent Director
--
--
Mr. Ryan Bond
Mr. Ryan Bond
Chief Strategy Officer
Chief Strategy Officer
--
--
Ms. Amanda Williams
Ms. Amanda Williams
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
11
259.66K
0.00%
-139.82K
2025Q3
12
545.94K
0.00%
+109.55K
2025Q2
10
436.38K
0.00%
+23.25K
2025Q1
9
413.13K
0.00%
-140.13K
2024Q4
9
486.12K
0.00%
+3.71K
2024Q3
9
482.41K
0.00%
+36.19K
2024Q2
10
556.22K
0.00%
-175.13K
2024Q1
10
731.36K
0.00%
-438.75K
2023Q4
10
1.26M
0.00%
+85.29K
2023Q3
10
1.17M
0.00%
+4.97K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Palisades Hudson Asset Management, L.P.
56.00K
0%
+56.00K
--
Sep 30, 2025
Clear Street Group Inc
47.22K
0%
+47.22K
--
Sep 30, 2025
CAPTRUST Financial Advisors
78.40K
0%
--
--
Sep 30, 2025
Clear Street LLC
47.12K
0%
--
--
Jun 30, 2025
Citadel Advisors LLC
--
0%
-40.00K
-100.00%
Mar 31, 2025
Armistice Capital LLC
--
0%
-34.38K
-100.00%
Mar 31, 2025
UBS Financial Services, Inc.
120.00
0%
+120.00
--
Sep 30, 2025
Warberg Asset Management LLC
--
0%
-15.00K
-100.00%
Jun 30, 2024
Hudson Bay Capital Management LP
--
0%
-160.00K
-100.00%
Jun 30, 2024
BofA Global Research (US)
437.00
0%
+100.00
+29.67%
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Aclarion Inc?
The top five shareholders of Aclarion Inc are:
Palisades Hudson Asset Management, L.P. holds 56.00K shares, accounting for 0.00% of the total shares.
Clear Street Group Inc holds 47.22K shares, accounting for 0.00% of the total shares.
CAPTRUST Financial Advisors holds 78.40K shares, accounting for 0.00% of the total shares.
Clear Street LLC holds 47.12K shares, accounting for 0.00% of the total shares.
Citadel Advisors LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Palisades Hudson Asset Management, L.P. holds 56.00K shares, accounting for 0.00% of the total shares.
Clear Street Group Inc holds 47.22K shares, accounting for 0.00% of the total shares.
CAPTRUST Financial Advisors holds 78.40K shares, accounting for 0.00% of the total shares.
Clear Street LLC holds 47.12K shares, accounting for 0.00% of the total shares.
Citadel Advisors LLC holds 0.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Aclarion Inc?
The top three shareholder types of Aclarion Inc are:
Other
Other
How many institutions hold shares of Aclarion Inc (ACONW)?
As of 2025Q4, 11 institutions hold shares of Aclarion Inc, with a combined market value of approximately 259.66K, accounting for --% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Aclarion Inc?
In --, the -- business generated the highest revenue for Aclarion Inc, amounting to -- and accounting for --% of total revenue.
